Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

Other illness

• Known allergy to Ameluz
• Photosensitivity or photodermatoses or similar conditions.
• Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol, in the opinion of the investigator
• Known hypersensitivity to porphyrins or to any component of Ameluz, including soya bean phosphatidylcholine.

Age

• Patients who are \<18 years of age

Other

• Adults who are unable to provide informed consent.
• Females who are currently breast-feeding

• Adults ≥ 18 years of age.
• Histologic proof of non-melanoma skin cancer. Patients with different skin tones based on the Fitzpatrick Scale, who present with skin growth or lesions and are scheduled for resection.
• As determined by the enrolling physician or study team member, the patient must have the willingness and ability to understand and comply with study procedures.
• Women of childbearing potential (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12-months and capable to become pregnant, must have a negative serum beta-HCG pregnancy test result within seven days prior to start of study.
• Lesions must measure between 5 mm and 3 cm in diameter.